Biosimilars Market Research Reports & Industry Analysis

Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.

The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.

The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.

Found 129 publications
Bevacizumab Biosimilar-United States Market Status and Trend Report 2013-2023 US$ 3,480.00

... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the United States Bevacizumab Biosimilar market as: United ...

Nov, 2017 158 pages
Bevacizumab Biosimilar-South America Market Status and Trend Report 2013-2023 US$ 3,480.00

... Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the South America Bevacizumab Biosimilar market as: South America Bevacizumab Biosimilar ...

Nov, 2017 160 pages
Bevacizumab Biosimilar-North America Market Status and Trend Report 2013-2023 US$ 3,480.00

... Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the North America Bevacizumab Biosimilar market as: North America Bevacizumab Biosimilar ...

Nov, 2017 135 pages
Bevacizumab Biosimilar-India Market Status and Trend Report 2013-2023 US$ 2,980.00

... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the India Bevacizumab Biosimilar market as: India Bevacizumab ...

Nov, 2017 138 pages
Bevacizumab Biosimilar-Global Market Status and Trend Report 2013-2023 US$ 2,480.00

Report Summary Bevacizumab Biosimilar-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers’ perspective, delivering detailed market data and ...

Nov, 2017 154 pages
Bevacizumab Biosimilar-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data US$ 3,680.00

... Bevacizumab Biosimilar-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers’ perspective, delivering detailed market data in Global ...

Nov, 2017 148 pages
Bevacizumab Biosimilar-Europe Market Status and Trend Report 2013-2023 US$ 3,480.00

... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the Europe Bevacizumab Biosimilar market as: Europe Bevacizumab ...

Nov, 2017 133 pages
Bevacizumab Biosimilar-EMEA Market Status and Trend Report 2013-2023 US$ 3,480.00

Report Summary Bevacizumab Biosimilar-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Bevacizumab Biosimilar industry, standing on the readers’ perspective, delivering detailed market data and ...

Nov, 2017 132 pages
Bevacizumab Biosimilar-China Market Status and Trend Report 2013-2023 US$ 2,980.00

... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the China Bevacizumab Biosimilar market as: China Bevacizumab ...

Nov, 2017 157 pages
Bevacizumab Biosimilar-Asia Pacific Market Status and Trend Report 2013-2023 US$ 3,480.00

... Bevacizumab Biosimilar market Market status and development trend of Bevacizumab Biosimilar by types and applications Cost and profit status of Bevacizumab Biosimilar, and marketing status Market growth drivers and challenges The report segments the Asia Pacific Bevacizumab Biosimilar market as: Asia Pacific ...

Nov, 2017 147 pages
Global Biosimilar Monoclonal Antibodies Market: Trend Analysis and Forecast to 2022 US$ 4,195.00

... the companies to invest in the biosimilar monoclonal antibodies market. SEGMENTS COVERED: The report segments the global biosimilar monoclonal antibodies market by drug class and by application. The biosimilar monoclonal antibodies market is driven by rituximab and ...

Dec, 2016 100 pages
Commercialisaton of Biosimilars: Multifunctional teamwork for success US$ 2,245.00

... believe companies need to choose 'a road less travelled'? Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle reveals what ... to optimal strategy development and implementation for biosimilars Key insights As the biosimilar market matures, commercial strategies will evolve to ...

Nov, 2017
Biosimilars Real World Evidence: Proving the point US$ 2,245.00

... prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence. In Biosimilars Real World Evidence: Proving the point ...

Jul, 2017
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update US$ 525.00

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2017 Update The Competitive Intelligence Report „Anti-VEGF & Anti-VEGF-R Biosimilars and Biosuperiors of Avastin ...

Nov, 2017 58 pages
The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis US$ 4,000.00 US$ 3,600.00

... with systemic agents. Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class ...

Oct, 2017 104 pages
Japan Biosimilars – A start of Authorized Biosimilar Era? Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market! US$ 4,000.00 US$ 3,600.00

... ~4000) and early entry of the player are critical factors to decide biosimilar penetration and market share dynamics of Japan Biosimilar Market. While ... in next few years for Japan biosimilar players. In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive landscape, ...

Aug, 2017 128 pages
Biosimilars Market in India 2017 US$ 1,995.00

Netscribes’ latest market research report titled Biosimilars Market in India 2017, describes the current and forecasted dynamics of the biosimilars market in India. The increasing ... has resulted in the growth of this industry in India. Biosimilars are typically marketed at prices that are 25% to 40% below the ...

Apr, 2017 43 pages
The Future of Biosimilars in Europe: Mapping critical uncertainties and the impact of future events US$ 2,245.00

... be involved in decisions about biosimilars? Will biosimilar oncology mAbs see widespread uptake? What should developers target next? For biosimilars to thrive, payers must ... on clinical and patient biosimilar experience Content Highlights Biosimilars in Europe: current status, key developments Key insights Overview The European biosimilars market continues ...

Jun, 2017
Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design US$ 2,995.00

... Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design' provides an in-depth assessment of the current trends in the global biosimilars market, with a particular focus on manufacturing complexities ...

Mar, 2017 117 pages
Global and Chinese Biologics and Biosimilars Industry, 2017 Market Research Report US$ 3,000.00

... 'Global and Chinese Biologics and Biosimilars Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Biologics and ... project of Biologics and Biosimilars Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Biologics and ...

Mar, 2017 150 pages
Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 US$ 2,600.00

The Global Biosimilar Drug Market Analysis & Forecast Report 2017-2022 is a professional and in-depth study on the current state of the Biosimilar Drug Market. The report analysis the global market of Biosimilar Drug by main manufactures and geographic regions. The report includes Biosimilar Drug definitions, classifications, applications and ...

Feb, 2017 105 pages
Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 US$ 1,500.00

... Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market ...

Feb, 2017 120 pages
Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon... US$ 1,200.00

... approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets ...

Jan, 2017 112 pages
2017-2022 Global Top Countries Biologics and Biosimilars Market Report US$ 4,960.00 US$ 4,364.80

... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in United States, Canada, ... by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top 5 players in these Countries, from 2012 to 2017 ( ...

Dec, 2016 126 pages
2017 Top 5 Biologics and Biosimilars Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa US$ 4,960.00 US$ 4,364.80

... and is sent in 48 hours after order is placed. This report studies Biologics and Biosimilars in Global market, especially in North America, Europe, Asia ... , revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico ... , this report focuses on sales, market share and growth rate of Biologics and Biosimilars in each application, can be divided into Tumor Diabetes ...

Dec, 2016 126 pages
2016 Global Biosimilars Market Status, 2011-2022 Market Historical and Forecasts, Professional Market Research Report US$ 2,800.00

... Version Biosimilars Market Research Report is a deep market research report in this market. This report focused on global and regional market, major manufacturers, as well as the segment market ... 2. Then the global and regional market is analyzed. In these chapters, this report analyzed major market data like capacity, production, capacity utilization ...

Dec, 2016 134 pages
Global Biologics and Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2021 US$ 3,480.00

... Other Market Segment by Applications, can be divided into Tumor Diabetes Cardiovascular Hemophilia Other There are 13 Chapters to deeply display the global Biologics and Biosimilars market. Chapter 1, to describe Biologics and Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Biologics and Biosimilars ...

Dec, 2016 110 pages
Global Biosimilar Market: Size, Trends & Forecasts (2016-2020) US$ 800.00

... “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share ... current and future trends. Sandoz, Amgen, Celltrion and Pfizer are some of the key players operating in the global biosimilar market whose company profiling ...

Nov, 2016 58 pages
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update US$ 1,393.00

... about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar ... , pavilizumab, tocilizumab, and ustekinumab. Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update Competitor projects are listed in a tabular format providing information ...

May, 2016 462 pages
Global and Chinese Biosimilars Industry, 2016 Market Research Report US$ 2,800.00

... 'Global and Chinese Biosimilars Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Biosimilars industry with a focus on the Chinese market ... a new project of Biosimilars Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Biosimilars industry covering all important ...

Nov, 2016 150 pages
Remicade (Infliximab) Biosimilar Clinical Trial Insight US$ 1,200.00

... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...

Oct, 2016 50 pages
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight US$ 1,000.00

... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...

Oct, 2016 35 pages
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight US$ 1,500.00

... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...

Oct, 2016 85 pages
Humira Biosimilars Clinical Trial Insight US$ 1,500.00

... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...

Oct, 2016 80 pages
Enbrel Biosimilars Clinical Trial & Opportunity Insight US$ 1,500.00

... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...

Oct, 2016 70 pages
Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis US$ 1,350.00

... 1. Global Biosimilars Market and Forecast - By Product Type 2. Global Biosimilars Market and Forecast - By Applications 3. Global Biosimilars Market and Forecast - By Country Wise 4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 5. Country with Biosimilar Guideline ...

Oct, 2016 177 pages
EPO Biosimilars - The Future of Erythropoietin Market US$ 600.00

... . However, the biosimilar versions of these drugs are expected to witness precipitous growth owing to their low cost. As per RNCOS report “EPO Biosimilars - The ... segmented into biologic and biosimilar erythropoietin markets. The report also highlights the various biologic and biosimilar erythropoietin drugs currently available ...

Aug, 2016 45 pages
Analyzing the Global Biosimilars Industry 2016 US$ 1,100.00

... of biosimilars is growing. Aruvian Research analyzes the global biosimilars industry in its research report Analyzing the Global Biosimilars Industry 2016. In this research report, we analyze what biosimilars are ... nature of biosimilars and the types of biologics available and role of biosimilars are also analyzed, along with the importance of biosimilars and a comparison between biosimilars and ...

Jul, 2016 285 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update US$ 560.00

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel and Remicade ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 124 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 84 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update US$ 280.00

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 56 pages
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update US$ 335.00

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-CD20 Antibodies 2016 updates the ... comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the ...

May, 2016 74 pages
Biosimilars in Oncology: Update Bulletin [Feb 2016] US$ 995.00

... on the latest events that have the potential to shape the oncology biosimilars market. Topics covered include opinions about data from Sandoz ... drive down prices to unsustainable levels and cause the biosimilars market in the US to fail? Update Bulletins include expert insight and analysis based on FirstWord ...

Feb, 2016
Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors US$ 220.00

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors This Competitive Intelligence report titled PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors“ provides a competitor evaluation in the field of protein- and peptide-based agonists of the parathyroid hormone (PTH) receptor ...

Feb, 2016 32 pages
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update US$ 440.00

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field ...

Feb, 2016 46 pages
Biosimilars in Oncology: KOL Insight US$ 7,900.00

... to accept biosimilars of proven targeted treatments. So what do pharma companies need to do to increase confidence and ensure uptake of biosimilars in this toughest of markets? Biosimilars in Oncology: KOL Insight spells out the concerns about equivalence, evidence and endpoints with insights into the current ...

Jan, 2016
Biosimilars: Regulatory Outlook US$ 2,100.00

... significant regulatory progress has been made in recent years, clarity is distinctly lacking on certain issues, such as interchangeability and naming.  FirstWord’s Biosimilars: Regulatory Outlook provides insight and opinion on why. This 64 page report gives in-depth and candid views on what eight industry and biosimilar experts ...

Nov, 2015
US Biosimilars Market Opportunity & Clinical Pipeline Analysis US$ 2,400.00

... Biosimilars Market Impact of Biosimilars in US Market Impact of Reimbursement Policies on US Biosimilars Market Zarxio: First Approved Biosimilar in US US Biosimilar Clinical Pipeline By Company, Indication & Phase US Biosimilar Clinical Pipeline: 104 Biosimilars Marketed Biosimilars: 1 Biosimilar ...

Feb, 2016 330 pages
The 2018-2023 World Outlook for Biosimilars US$ 995.00

This study covers the world outlook for biosimilars across more than 190 countries. For each ... unavailable, in a comparable or consistent manner in virtually all of the countries of the world). This study gives, however, my estimates for the worldwide latent ...

Apr, 2017 292 pages
Biosimilars Market: By Product (Recombinant Glycosated Proteins, Others) Technology (Chromatography, Mass Spectroscopy, Electrophoresis, Others) Application (Blood & Oncology Diseases,... US$ 5,250.00 US$ 4,200.00

... and comprehensive analysis of biosimilars market Regulations for biosimilars play a vital role as they maintain a balance between original & biosimilar products. Currently the geographic biosimilar market is segmented into ...

Aug, 2015 86 pages
1 2 3 >
Skip to top